IMMEDIATE Therapeutics (IMMTX) is advancing IMT-358, a first-in-class metabolic cardioprotective therapy targeting the largest remaining unmet need in acute cardiovascular care: protecting myocardium during active ischemia. While current standards restore blood flow, no approved therapy preserves cardiac muscle before reperfusion.

In a randomized Phase 2 trial, IMT-358 demonstrated ~80% reduction in infarct size and ~50% reduction in cardiac arrest/mortality composite when administered early in the field. The program has received FDA Breakthrough Therapy Designation and Special Protocol Assessment support and is advancing toward a single pivotal Phase 3 trial.

With expansion potential across surgery, trauma, stroke, and cardio-oncology, IMT-358 represents a scalable cardiometabolic platform positioned to redefine ischemic care globally.